Rheumatoid Arthritis Treatment, Product Administration, Training and Patient Assistance/Compassionate Use Program Awareness for the Specialty

Size: px
Start display at page:

Download "Rheumatoid Arthritis Treatment, Product Administration, Training and Patient Assistance/Compassionate Use Program Awareness for the Specialty"

Transcription

1 Rheumatoid Arthritis Treatment, Product Administration, Training and Patient Assistance/Compassionate Use Program Awareness for the Specialty Pharmacist and the Collaborative Healthcare Team

2 Disclaimer The information within this CME/CE activity is for continuing education purposes only, and is not intended to substitute for the medical judgment of the healthcare provider. Recommendations for use of any particular therapeutic agents or methods are based upon the best available scientific evidence and clinical guidelines. Reference in this activity to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation. Developer discloses that he is a speaker, consultant, and provides research support for the National Association of Specialty Pharmacy. He does not intend to discuss non-fda approved drugs or investigational use of any product/device.

3 Faculty Biography University of Florida 2008 Pharmacist in Charge Publix Super Markets National Association of Specialty Pharmacy Specialty Pharmacy Clinical Consultant Michael J Crocco, PharmD, RPh, CSP Specialty Pharmacy Clinical Services National Association of Specialty Pharmacy Specialty Pharmacy Education Center Reviewer/author of CE s Specialty Pharmacy Certification Board Subject matter expert in developing Certified Specialty Pharmacy Credential Certified Specialty Pharmacist

4 Objectives Recognize the various inflammatory autoimmune disorders and their distinguishing features. Identify current treatment options for RA and review their appropriate administration Identify the three biggest barriers to adherence & persistence and how Specialty Pharmacists and the collaborative healthcare team can anticipate & overcome those barriers Identify RA patient assistance programs from RA manufacturers and 3 rd parties Describe the specialty pharmacist and the collaborative healthcare team s role in RA condition management resulting in cost-effective care

5 Other Autoimmune Diseases (Brief Overview)

6 Crohn s Disease Inflammatory Bowel Disease Lining of digestive tract (mouth to anus) Signs/Symptoms Abdominal pain Severe diarrhea Blood in stool Ulcers Reduced appetite Weight loss e.svg

7 Ulcerative Colitis Inflammatory bowel disease Lining of large intestine Types of UC: Proctitis Proctosigmoiditis Left-sided Colitis Pancolitis Fulminant Colitis pg

8 Psoriatic Arthritis Enthesitis Characteristic feature Signs/Symptoms Similar to RA, plus.. Swollen fingers and toes Foot pain Lower back pain

9 Juvenile Idiopathic Arthritis Children 6 months 16 years old Types of JIA Pauciarticular Polyarticular Systemic

10 Juvenile Idiopathic Arthritis Symptoms Pain Swelling Stiffness Swollen lymph nodes Rash Fever

11 Ankylosing Spondylitis Spine Vertebrae fuse Signs/Symptoms Lower back pain Hip pain

12 Treatment Options Rheumatoid Arthritis

13 DMARDs Methotrexate (Trexall, Rheumatrex) Leflunomide (Arava) Hydroxychloroquine (Plaquenil) Sulfasalazine (Azulfidine)

14 Methotrexate Dosing Once weekly Oral or injection (IM or SQ) Titrate up as necessary Hydration Monitoring LFT s CBC w/diff Platelets BUN/Cr

15 htm Methotrexate SQ Injection 25 Gauge 1/2-5/8 inch

16 Methotrexate IM Injection 25 Gauge inch htm

17 Leflunomide Dosing Loading dose of 100mg x 3 days 20mg daily thereafter With food Monitoring BP Platelets WBC s Hgb/Hct LFT s

18 Leflunomide Drug elimination procedure Cholestyramine 8g TID x 11 days Plasma levels <0.02mg/dL 2 tests, 14 days apart If no elimination procedure Up to 2 years to reach <0.02mg/dL

19 Hydroxychloroquine Weight based dosing 6.5mg/kg /day Typically mg daily Monitoring Eye exams Yearly Keep away from children Small doses fatal

20 Sulfasalazine Dosing mg Q12H Up to 4000mg daily Monitoring CBC w/diff LFTs BUN/Cr Caution Sulfonamide allergy Salicylate allergy

21 TNFa Inhibitors Humira (Adalimumab) Enbrel (Etanercept) Cimzia (Certolizumab pegol) Simponi (Golimumab) Remicade (Infliximab)

22 Humira Dosing 40mg SQ q2wk 40mg SQ qwk if not on MTX Refrigerate Monitor Hep B antigen PPD s/sx TB and HBV Cost $2400-$2700 (2 pens/syringes)

23 Humira Administering Pen Clear/colorless liquid No particles Front of thighs/lower abdomen Clean area Gently squeeze skin and hold firmly Hold pen at 90 degree angle Push plum colored button until clicks Hold for 10 seconds Yellow Indicator = Completed Do not rub area 2IpGLsVangU/UEktd63ThII/AAAAAAAAAJw/wmt8vVOYiC8/s1600/humira1.jpg

24 Humira Administering Prefilled Syringe Clear/colorless liquid No particles Front of thighs/lower abdomen Clean area Gently squeeze skin and hold firmly Insert at 45 degree angle and let go of skin After injecting, remove at same angle Do not rub area 8QaFwE1vRfE/T819tbn5jQI/AAAAAAAAACk/gAjBd3WTGPo/s1600/humira.jpg

25 Humira Patient Assistance Programs myhumira Humira Protection Plan 24/7 on-call nurse support HUMIRA Injection training kit Sharps container Medication reminders On-the-go kit Abbvie Patient Assistance Foundation

26 Enbrel Dosing 50mg SQ qwk OR 25mg SQ 2x/wk 72-96h apart Storage Refrigerate Room temperature 14 days Monitor Hep B antigen PPD s/sx TB and HBV Dermatologic exam* Cost $2200-$3000

27 Enbrel Administering SureClick AutoInjector Clear/colorless liquid Front of thighs preferred Abdomen/outer are of upper arms Clean area Stretch skin to make it firm and taut Hold pen at 90 degree angle Press pen firmly to unlock safety guard Press and release purple button Hold firmly for 15 seconds Purple Indicator = Completed Do not rub area pg

28 Enbrel Administering Enbrel PFS Clear/colorless liquid Front of thighs/lower abdomen/outer upper arms Clean area Gently squeeze skin and hold firmly Inject at 45 degree angle Do not rub area

29 Enbrel PAP Enbrel Support Card Education Injection training Medication refill reminders Live nurse support ENBREL Starter kit Sharps mail-back program Travel pack

30 Enbrel Support Card If commercial insurance: $0 for 6 months, $10 afterwards If Government insurance: Connect with independent foundations Low-income subsidy assistance If Uninsured: ENcourage Foundation

31 Cimzia Dosing 400mg SQ on week 0, 2, 4, then 200mg SQ q2wk OR 400mg SQ q4wk Refrigerate Monitor Hep B antigen PPD s/sx TB and HBV Dermatologic exam* Cost ~$2500

32 Cimzia Administration Room temperature 30 minutes Clear/colorless liquid Front of thighs/lower abdomen Clean area Gently squeeze skin and hold firmly Inject at 45 degree angle Do not rub area

33 Cimzia PAP Cimplicity Treatment and patient support Home Health Nurse CIMZIA Education Injection training Insurance coverage verification Cimzia Co-pay Savings Card Program Up to 12 months at no cost Additional financial assistance

34 Simponi Dosing 50mg SQ monthly with MTX Refrigerate Monitor Hep B antigen PPD s/sx TB and HBV Dermatologic exam* Cost ~$8300 (5 syringes)

35 Simponi SmartJect Autoinjector Administration Room temperature 30 minutes Clear/slightly yellow Front of thighs/lower abdomen/outer area of upper arms Clean area Inject at 90 degree angle Press firmly against skin to unlock safety sleeve Press button until clicks hold until clicks again Do not rub area Shot.jpg

36 Simponi Prefilled Syringe Administration Room temperature 30 minutes Clear/slightly yellow Front of thighs/lower abdomen/back of upper arms Clean area Gently squeeze skin and hold firmly Inject at 45 degree angle Hold plunger until removed from skin then release Do not rub area PG

37 SimponiOne Support Injection Support Nurse Support MY SIMPONI RN Live Link (on-line discussion) 7 days/wk, 8am-11pm SmartJect Autoinjector Reusable Trainer Included in Welcome Pack Demonstration Videos

38 SimponiOne Support Treatment Support Simponi Welcome Pack SimponiOne Safe Returns Once a year return service Holds 12 SmartJect autoinjectors Holds more syringes Travel Pack Travel Advisory Card

39 SimponiOne Support Medication Cost Support Commercial/Private Insurance $5/month up to $8000 benefit/yr Government Insurance independent foundation No insurance Johnson & Johnson Patient Assistance Foundation Other

40 Remicade Dosing 3mg/kg IV on wk 0, 2, 6 THEN 3mg/kg IV q8wk Use with MTX Max dose 10mg/kg OR 3mg/kg q4wk Refrigerate Monitor Hep B antigen PPD s/sx TB and HBV Dermatologic exam* Cost $ for one vial (100mg)

41 Remicade Administration Colorless/light yellow By medical professional Infusion Center At least 2 hours

42 Remicade PAP AccessOne Care Coordinator Access-1 M-F, 8am-8pm EST Infusion site locations Newsletters Education materials Appointment reminders Emergency outreach services

43 Remicade PAP RemiStart Patient Rebate Program Co-pay assistance Up to 12 months, 8 infusions, or $8000 RemiStart Extended Access Program Must meet eligibility requirements

44 Other Biologics Kineret (Anakinra) Orencia (Abatacept) Rituxan (Rituximab) Actemra (Tocilizumab)

45 Kineret Dosing 100mg SQ q24h Refrigerate Monitor Cr ANC Pregnancy Category B Cost ~$3000/28 syringes

46 Kineret Prefilled Syringe Administration Sit at room temperature minutes Clear/colorless Sites Outer area of upper arms Upper outer areas of buttocks Abdomen Front of the middle thighs Gently pinch fold of skin Inject at 45 or 90 degree angle gif

47 Kineret PAP KineretKare Program Copay assistance Up to $300/month OR $3600/year Delivery of medication Access to KineretKare specialist M-F, 8am-6pm EST

48 Orencia Weight based dosing <60kg 500mg IV on wk 0, 2, 4, then q4wk OR 500mg IV x1, then 125mg SQ w/in 24hr, then 125mg SQ qwk kg same as above but 750mg IV doses >100kg same as above but 1000mg IV doses Refrigerate Monitor Cost Hepatitis panel PPD at baseline $2100/vial (250mg) $2500/4 syringes (125mg)

49 Orencia Administration IV Medical professional Reconstitute with 10ml sterile water for injection Must use silicone free syringe provided 30 minute infusion

50 Orencia Administration SQ Clear/colorless/pale yellow Room temperature minutes Sites Front of thigh Upper outer arms Abdomen Gently pinch skin and hold firmly Inject at 45 degree angle Ulnq7gEQ1NM/UqNeD7LnvSI/AAAAAAAATEo/vQpbAc01osY/s1600/orencia.jpg

51 Orencia PAP Orencia On Call Personal care counselor Available 24/ ORENCIA Copay assistance Welcome pack Sharps Disposal Service Drug Replacement If damaged Insurance questions

52 Orencia PAP Orencia Copay Assistance Program Covers cost of drug only Infusion patients $5 out of pocket per infusion $8000/year max benefit NOTE: state or federally funded insurance excluded

53 Rituxan Dosing 1000mg IV on days 1 and 15 THEN 1000mg IV q24 weeks Q16 weeks In combination with MTX Refrigerate Cost ~$15,600 (one 10ml vial = 10mg/ml)

54 Rituxan Monitoring HBsAg Anti-HBc at baseline CBC Platelets ECG s/sx of hepatitis or HBV reactivation

55 Rituxan Administration IV infusion Medical professional Pre-medicate APAP and antihistamine Methylprednisolone 100mg IV (RA patients only)

56 Rituxan Infusion Rates Initial Infusion = 50mg/hr Increase at 50mg/hr increments q30 minutes Max 400mg/hr Subsequent infusions = 100mg/hr Increase at 100mg/hr at 30 minute intervals Max 400mg/hr

57 Rituxan PAP Join Rituxan and You Genentech Rheumatology Access Solutions Genentech Access to Care Foundation Genentech Rheumatology Co-pay Card Program $10,000 over 12 months $5 per co-pay May reuse if still eligible after 12 months

58 Actemra IV Dosing 4mg/kg IV over 1 hour q4wks May increase to 8mg/kg IV q4wks Do not exceed 800mg per infusion SQ Dosing 162mg SQ qwk If pt <100kg, start at 162mg SQ q2wks Refrigerate Cost $340 (4ml vial) $850 (10ml vial) $1725 (20ml vial)

59 Actemra Monitoring PPD at baseline s/x of TB CBC w/differential (ANC s) Platelets LFT s Lipid profile

60 Actemra Administration IV Infusion Clear/colorless/pale yellow Medical professional Room temperature Infuse over 60 minutes Use separate IV line pg

61 Actemra Administration SQ Room temperature 30 minutes Sites Front of thigh Outer area of upper arm Abdomen Gently pinch skin Inject at 45 or 90 degree angle Release pinched skin and inject

62 Actemra PAP Actemra Access Sampling Program SQ patients ACT Fast Program 6 months free Support for Medicare Part D patients Refer to LIS Program Genentech Access to Care Foundation Extension

63 Actemra Access Actemra and You Symptom Tracker Calendar Doctor Discussion Guide Nurse Help Line ACTEMRA 6am-12am EST SC Injection tools Travel Pack Sharps Container Injection Reminder Service Treatment Tracker

64 Actemra Access Genentech Rheumatology Co-pay Card Program $10,000 per 12 months $5 co-pay Genentech Rheumatology Access Solutions

65 JAK inhibitor Xeljanz (Tofacitinib)

66 Xeljanz Dosing 5mg PO BID With or w/o food Room temperature Monitoring CBC w/diff Lipid panel LFT s Cost ~$2,000 (60 tablets)

67 XelSource Private Insurance Free Trial Offer Personal Support M-F, 8am-8pm EST Xeljanz Copay Savings Card $0 copay $8,000 benefit per calendar year Uninsured XelSource Patient Assistance Program

68 Xeljanz Government Insurance Personal Support Financial Assistance State Pharmaceutical Companies Low-income subsidies Charitable foundations Hardship support Xeljanz + You Welcome Kit Refill reminders Tips, Tools, and Resources

69 Other Patient Assistance Programs NeedyMeds Diplomat s Co-pay Assistance Navigator HealthWell Foundation Patient Access Network Foundation Bristol-Myers Squibb Patient Assistance Foundation Orencia Pfizer Pfriends Xeljanz

70 Other Patient Assistance Programs Partnership for Prescription Assistance Humira MedLink Prescription Assistance Enbrel Janssen Prescription Assistance Simponi, Remicade Johnson & Johnson Prescription Assistance Foundation Remicade

71 Barriers to Adherence Cost Direct Indirect Administration Complicated/intimidating Transportation/Time Infusions Side effects Cancer Infertility Pain

72 Overcoming Barriers Treatment management Counsel/Educate Side effects Self injections Insurance No more pre-existing condition Use assistance programs Home health nurse Specialty Pharmacist

73 Conclusion Multiple treatment options Biologics are expensive All have assistance programs Make patients aware Need to educate/counsel all patients

74 References Mayoclinic. Crohn s Disease. Accessed on November 19, Crohn s and Colitis Foundation of America. What is Crohn s Disease? Accessed on November 19, Mayoclinic. Ulcerative Colitis. Accessed on November 19, Crohn s and Colitis Foundation of America. What is Ulcerative Colitis. Accessed on November 19, American College of Rheumatology. Psoriatic Arthritis. Psoriatic_Arthritis/. Accessed on November 21, Mayoclinic. Psoriatic Arthritis. Accessed on November 21, 2013.

75 References Mayoclinic. Juvenile Rheumatoid Arthritis. Accessed on November 21, National Institute of Arthritis and Musculoskeletal and Skin Diseases. What is Juvenile Arthritis? Accessed on November 21, WebMD. Understanding Juvenile Rheumatoid Arthritis. Accessed on November 21, Mayoclinic. Ankylosing Spondylitis. Accessed on November 22, American College of Rheumatology. Methotrexate. xate_(rheumatrex,_trexall)/. Accessed on November 22, 2013.

76 References Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Department of Pharmacy Practice, University of Georgia College of Pharmacy, Athens. Arthritis Rheum Jan;33(1):91-4. Mayoclinic. Leflunomide. Accessed on November 24, Sanofi-Aventis. Arava Package Insert. Accessed on November 24, Mayoclinic. Hydroxychloroquine. Accessed on December 5, Mayoclinic. Sulfasalazine. Accessed on December 5, 2013.

77 References Patient Assistance Programs. Accessed January 20, 2014 February 27, Humira Product Information and Patient Assistance Programs. Accessed on January 15, Enbrel Product Information and Patient Assistance Programs. Accessed on January 15, Cimzia Product Information and Patient Assistance Programs. Accessed on January 16, Simponi Product Information and Patient Assistance Programs. Accessed on January 16, Remicade Product Information and Patient Assistance Programs. Accessed on January 18, Kineret Product Information and Patient Assistance Programs. Accessed on January 24, 2014.

78 References Orencia Product Information and Patient Assistance Programs. Accessed on January 31, Rituxan Product Information and Patient Assistance Programs. Accessed on February 10, Actemra Product Information and Patient Assistance Programs. Accessed on February 12, Xeljanz Product Information and Patient Assistance Programs. Accessed on February 15, Micromedex Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Epocrates Epocrates Mobile Application. Retrieved from

79 Q & A

80 This program has been brought to you by The National Association of Specialty Pharmacy and its education provider The Specialty Pharma Education Center. Claim Credit Instructions: Visit & type session code: (session codes are also located in your program guide on the activity sheet page) *All users must complete the pre AND post test to receive statement of credit. Credit must be claimed within 30 days of this program.

RHEUMATOID ARTHRITIS DRUGS

RHEUMATOID ARTHRITIS DRUGS Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi

More information

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review

More information

The ORENCIA (abatacept) JIA Observational Registry

The ORENCIA (abatacept) JIA Observational Registry Moderate to Severe Juvenile Idiopathic Arthritis (JIA) Injection for Intravenous Use Injection for Subcutaneous Use The ORENCIA (abatacept) JIA Observational Registry Injection for Intravenous Use Injection

More information

Get an Insurance Benefits Review for ORENCIA (abatacept)

Get an Insurance Benefits Review for ORENCIA (abatacept) Get an Insurance Benefits Review for ORENCIA (abatacept) If you and your doctor decide that ORENCIA is right for you, you can call 1-800-ORENCIA (1-800-673-6242) to do an Insurance Benefits Review. Our

More information

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)

More information

Cosentyx. Cosentyx (secukinumab) Description

Cosentyx. Cosentyx (secukinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx

More information

(continued) MEDICATION GUIDE Rx Only KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use

(continued) MEDICATION GUIDE Rx Only KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use MEDICATION GUIDE KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use Rx Only What is the most important information I should know about KEVZARA? KEVZARA can cause serious side effects including:

More information

PATIENT INFORMATION. ORENCIA (oh-ren-see-ah) (abatacept) Lyophilized Powder for Intravenous Infusion

PATIENT INFORMATION. ORENCIA (oh-ren-see-ah) (abatacept) Lyophilized Powder for Intravenous Infusion PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Lyophilized Powder for Intravenous Infusion ORENCIA (oh-ren-see-ah) (abatacept) Injection, Solution for Subcutaneous Administration Read this Patient

More information

Easy as knowing how to take the next step.

Easy as knowing how to take the next step. To enroll and activate: Visit Simponi.JanssenCarePathSavings.com For adults with moderate to severe rheumatoid arthritis (RA) with methotrexate, active psoriatic arthritis alone or with methotrexate, or

More information

Simponi / Simponi ARIA (golimumab)

Simponi / Simponi ARIA (golimumab) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi

More information

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

MEDICATION GUIDE Rx Only KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use What is the most important information I should know about

MEDICATION GUIDE Rx Only KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use What is the most important information I should know about MEDICATION GUIDE KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use Rx Only What is the most important information I should know about KEVZARA? KEVZARA can cause serious side effects including:

More information

Otezla. Otezla (apremilast) Description

Otezla. Otezla (apremilast) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background

More information

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date: Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

MEDICATION GUIDE SIMPONI (SIM-po-nee) (golimumab)

MEDICATION GUIDE SIMPONI (SIM-po-nee) (golimumab) MEDICATION GUIDE SIMPONI (SIM-po-nee) (golimumab) Read the Medication Guide that comes with SIMPONI before you start taking it and each time you get a refill. There may be new information. This Medication

More information

INSTRUCTIONS FOR USE ORENCIA (oh-ren-see-ah) (abatacept) Prefilled Syringe with BD UltraSafe Passive Needle Guard

INSTRUCTIONS FOR USE ORENCIA (oh-ren-see-ah) (abatacept) Prefilled Syringe with BD UltraSafe Passive Needle Guard INSTRUCTIONS FOR USE ORENCIA (oh-ren-see-ah) (abatacept) Prefilled Syringe with BD UltraSafe Passive Needle Guard ORENCIA Prefilled Syringe with BD UltraSafe Passive TM Needle Guard (abatacept) Injection

More information

Stelara. Stelara (ustekinumab) Description

Stelara. Stelara (ustekinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi

More information

First Name. Specialty: Fax. First Name DOB: Duration:

First Name. Specialty: Fax. First Name DOB: Duration: Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and

More information

BACK FIGHT. It s time to. Take action today. Ask your rheumatologist about ORENCIA.

BACK FIGHT. It s time to. Take action today. Ask your rheumatologist about ORENCIA. For moderate to severe Rheumatoid Arthritis (RA) It s time to FIGHT BACK Model, not actual patient. Take action today. Ask your rheumatologist about ORENCIA. What is ORENCIA? ORENCIA (abatacept) is a prescription

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance

More information

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,

More information

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),

More information

Center for Evidence-based Policy

Center for Evidence-based Policy P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N

More information

Actemra. Actemra (tocilizumab) Description

Actemra. Actemra (tocilizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra

More information

MEDICATION GUIDE HUMIRA

MEDICATION GUIDE HUMIRA MEDICATION GUIDE HUMIRA (Hu-MARE-ah) (adalimumab) injection Read the Medication Guide that comes with HUMIRA before you start taking it and each time you get a refill. There may be new information. This

More information

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of

More information

o Your healthcare provider should test you for TB before starting CIMZIA.

o Your healthcare provider should test you for TB before starting CIMZIA. Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date:

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date: Clinical Policy: (Stelara) Reference Number: ERX.SPA.01 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Drug Class Review Targeted Immune Modulators

Drug Class Review Targeted Immune Modulators Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid

More information

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab

More information

KEEP UP THE FIGHT WITH. Little Victories

KEEP UP THE FIGHT WITH. Little Victories FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) KEEP UP THE FIGHT WITH Little Victories Small improvements in your daily activities may be a sign that ORENCIA (abatacept) is working for you. Use this

More information

Pharmacy Medical Necessity Guidelines: Orencia (abatacept)

Pharmacy Medical Necessity Guidelines: Orencia (abatacept) Pharmacy Medical Necessity Guidelines: Effective: October 23, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or

More information

MEDICATION GUIDE. (tocilizumab)

MEDICATION GUIDE. (tocilizumab) MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place

More information

MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)

MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not

More information

For Rheumatoid Arthritis

For Rheumatoid Arthritis For Rheumatoid Arthritis APRIL 2017 NOTICE: On April 14, 2017 the FDA issued a complete response letter for baricitinib indicating that the FDA is unable to approve the application in its current form

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)

More information

Clinical Policy: Anakinra (Kineret) Reference Number: ERX.SPA.135 Effective Date:

Clinical Policy: Anakinra (Kineret) Reference Number: ERX.SPA.135 Effective Date: Clinical Policy: (Kineret) Reference Number: ERX.SPA.135 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

WHAT YOU SHOULD KNOW ABOUT RoACTEMRA

WHAT YOU SHOULD KNOW ABOUT RoACTEMRA RoACTEMRA (tocilizumab) IV and SC for Rheumatoid Arthritis WHAT YOU SHOULD KNOW ABOUT RoACTEMRA This brochure provides key information to assist in the patient s understanding of the benefits and risks

More information

Carelirst.+.V Family of health care plans

Carelirst.+.V Family of health care plans Carelirst.+.V Family of health care plans CVS Caremark POLICY Document for ACTEMRA The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information

BIOLOGICS & What You Need to Know

BIOLOGICS & What You Need to Know BIOLOGICS & What You Need to Know Biologic are given to improve how your immune system works & helps to control your disease. They are highly specific genetic copies of human proteins, given as s or infusions

More information

Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date:

Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date: Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy

More information

certolizumab pegol (Cimzia )

certolizumab pegol (Cimzia ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

While every patient s experience is different, here are the general findings from clinical trials:

While every patient s experience is different, here are the general findings from clinical trials: Indications: CIMZIA (certolizumab pegol) is approved for the treatment of adults with moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis

More information

ORENCIA (oh-ren-see-ah) (abatacept)

ORENCIA (oh-ren-see-ah) (abatacept) 17.7 FDA-Approved Patient Labeling PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Read this Patient Information before you start receiving ORENCIA and each time before you are scheduled to receive

More information

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014 Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior

More information

Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date:

Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Biologics for Autoimmune Diseases

Biologics for Autoimmune Diseases Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines

More information

Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS

Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS Moderate to Severe Rheumatoid Arthritis (RA) 3 Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA (abatacept) is a prescription

More information

(tofacitinib) are met.

(tofacitinib) are met. Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically

More information

DEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT

DEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT LET US HELP YOU FIND A CLEARER PATH FORWARD. DEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT PERSONALIZED SUPPORT FREE MEDICATION* $0 CO-PAY* WELCOME KIT RECYCLABLE

More information

While every patient s experience is different, here are the general findings from clinical trials:

While every patient s experience is different, here are the general findings from clinical trials: Indications: CIMZIA (certolizumab pegol) is approved for the treatment of adults with moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber

More information

Clinical Policy: Tocilizumab (Actemra) Reference Number: CP.PHAR.263 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Tocilizumab (Actemra) Reference Number: CP.PHAR.263 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Actemra) Reference Number: CP.PHAR.263 Effective Date: 07.01.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the

More information

Drug Class Review Targeted Immune Modulators

Drug Class Review Targeted Immune Modulators Drug Class Review Targeted Immune Modulators Final Update 3 Report March 2012 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of the is to summarize

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) CIMZIA (certolizumab pegol) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

Orencia (abatacept) DRUG.00040

Orencia (abatacept) DRUG.00040 Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28

More information

Announcing HUMIRA. Psoriasis Starter Package

Announcing HUMIRA. Psoriasis Starter Package Announcing HUMIRA (adalimumab) Psoriasis Starter Package HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy

More information

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid

More information

Rheumatoid Arthritis Update. Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy

Rheumatoid Arthritis Update. Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy Rheumatoid Arthritis Update Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy Disclosures I declare that neither I nor any member of

More information

Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria

Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with

More information

Specialty Pharmacies: What they are. Why they are different.

Specialty Pharmacies: What they are. Why they are different. Specialty Pharmacies: What they are. Why they are different. A changing environment of medicines and pharmacies. Filling a prescription used to be as simple as going to the corner drug store. Today, the

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Simponi, Simponi Aria Applicable Medical Benefit x Effective: 2/13/18 Pharmacy- Formulary 1 x Next Review: 12/18 Pharmacy- Formulary 2 x Date of Origin: 7/2010 Pharmacy- Formulary 3/Exclusive x Review

More information

Medication Guide Enbrel (en-brel) (etanercept)

Medication Guide Enbrel (en-brel) (etanercept) Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide

More information

STEP-BY-STEP DOSING AND ADMINISTRATION GUIDE

STEP-BY-STEP DOSING AND ADMINISTRATION GUIDE RoACTEMRA (tocilizumab) Rheumatoid Arthritis (IV and SC formulation) and Giant Cell Arteritis (SC formulation only) STEP-BY-STEP DOSING AND ADMINISTRATION GUIDE A guide to assist healthcare professionals

More information

C. Assess clinical response after the first three months of treatment.

C. Assess clinical response after the first three months of treatment. Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit

More information

Amjevita (adalimumab-atto)

Amjevita (adalimumab-atto) *- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled

More information

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year

More information

A Clinical Context Report

A Clinical Context Report Rheumatoid Arthritis in Practice An Expert Commentary with Diane Horowitz, MD A Clinical Context Report Rheumatoid Arthritis in Practice Jointly Sponsored by: and Rheumatoid Arthritis in Practice Expert

More information

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine

More information

2017 Blue Cross and Blue Shield of Louisiana

2017 Blue Cross and Blue Shield of Louisiana Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis

More information

Kineret (anakinra) When Policy Topic is covered Kineret (anakinra) requires prior authorization through the pharmacy services area.

Kineret (anakinra) When Policy Topic is covered Kineret (anakinra) requires prior authorization through the pharmacy services area. Kineret (anakinra) Policy Number: 5.01.622 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Kineret (anakinra)

More information

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade

More information

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio

More information

Regulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 14 Last Review Date: June 22, 2018 Humira Description Humira (adalimumab),

More information

Clinical Policy: Sarilumab (Kevzara) Reference Number: CP.PHAR.346 Effective Date: Last Review Date: 11.18

Clinical Policy: Sarilumab (Kevzara) Reference Number: CP.PHAR.346 Effective Date: Last Review Date: 11.18 Clinical Policy: (Kevzara) Reference Number: CP.PHAR.346 Effective Date: 07.18.17 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Regulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 8 Last Review Date: March 16, 2018 Enbrel Description Enbrel (etanercept),

More information

Spring How will that pipeline drug impact my benefit plan?

Spring How will that pipeline drug impact my benefit plan? Spring 2012 How will that pipeline drug impact my benefit plan? How will that pipeline drug impact my benefit plan? It can be difficult to predict the impact pipeline drugs will have once they reach the

More information

Clinical Policy: Anakinra (Kineret) Reference Number: CP.PHAR.244 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Anakinra (Kineret) Reference Number: CP.PHAR.244 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Kineret) Reference Number: CP.PHAR.244 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Certolizumab pegol (Cimzia) for psoriatic arthritis second line

Certolizumab pegol (Cimzia) for psoriatic arthritis second line Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information